Form 4: BioLife Solutions CMO Sells Shares for Tax Obligations

BioLife Solutions Chief Marketing Officer Todd Berard sold 358 shares of common stock on September 11, 2025, to cover tax withholding obligations.

Summary

• Todd Berard, Chief Marketing Officer of BioLife Solutions Inc. (BLFS), reported a sale of common stock.
• The transaction involved 358 shares of common stock.
• The shares were sold at a price of $26.83 per share.
• The sale occurred on September 11, 2025.
• Following this transaction, Mr. Berard directly beneficially owns 133,906 shares of common stock.
• The sale was executed under a Rule 10b5-1(c) trading plan, which was adopted on March 8, 2024.
• The primary purpose of the sale was to satisfy tax withholding obligations associated with the vesting of restricted stock.

Sentiment

Score: 5

Explanation: The filing reports a routine, pre-planned insider transaction for tax purposes, which is generally considered neutral in terms of market sentiment.

Future Outlook

NA

Management Comments

• The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 03-08-2024 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

Industry Context

This is a standard insider transaction filing (Form 4) reporting a pre-planned sale of shares by an executive. Such sales, particularly when tied to tax obligations from restricted stock vesting and executed under a Rule 10b5-1 plan, are common across all industries and typically do not reflect a change in the executive's confidence in the company or broader industry trends.

Stakeholder Impact

• Shareholders: Minimal impact as it is a routine, pre-planned transaction for tax purposes, not indicative of a change in company fundamentals or management's outlook.

Key Dates

Recommendation

The filing details a routine, pre-planned sale of a small number of shares by a Chief Marketing Officer to cover tax obligations related to restricted stock vesting. This transaction is not indicative of a change in management's outlook or a significant shift in company fundamentals, thus it does not warrant a change in investment recommendation.

Keywords

BioLife Solutions, BLFS, Todd Berard, Insider Trading, Form 4, Stock Sale, CMO, Rule 10b5-1, Tax Withholding